The monkeypox virus “has significant differences with Covid, starting with the fact that it is not easily transmitted between humans; an increase in cases is likely but there is currently no health emergency”. This was stated by Marco Cavaleri, head of the vaccine strategy of the European Medicines Agency (Ema). “At the moment this is not a public health emergency and the focus should remain on identifying, monitoring and managing new cases,” Cavaleri concluded.
The epidemiological situation of Covid in Europe “is generally under control, the number of new and fatal infections is decreasing, but there is an increase in cases in some countries, most likely linked to the spread of Omicron BA variants. 4 and BA.5, identified for the first time in South Africa, “Cavaleri later said. These variants “could become dominant in the EU – he added – but from the data available so far they are not associated with more serious forms of disease”. “We maintain the recommendation – concluded Cavaleri – to administer a fourth dose or a second booster dose for people aged 80 and over, and we recommend to those who have not yet done so to complete the vaccination cycle”. “Significant progress” is expected in the coming weeks on adapted vaccines against Covid, said Cavaleri, reiterating that the goal is to give the green light to the first new vaccines in September. “Talks are underway with producers – explained Cavaleri – we are giving priority to products that cover the Omicron BA1 variant in addition to or in place of the original strain, the results of clinical tests are expected between June and August”. Cavaleri recalled that the EMA is examining not only the updating of vaccines already authorized but also their use in new age groups. The booster dose recommendation of Comirnaty, Pfizer-BioNTech’s vaccine, in children ages 5 to 11 may come “before the end of the month”. The demand for the use of Moderna in children aged 6 months to 5 years is also currently under examination and, said Cavaleri, “we are close to finalizing the evaluation in adolescents for the primary series of Nuvaxovid” (Novavax).
breaking latest news © Copyright ANSA
<![CDATA[]]>
var userAccept = $.cookie(‘cb-enabled’);
var cookieAccepted = (userAccept != null && userAccept.indexOf(‘accepted’) != -1);
if (cookieAccepted) {
(function($n,e,o,d,a,t,a$) {
$n._4wRecom = $n._4wRecom || {};
$n._4wRecom.Q = $n._4wRecom.Q || [];
$n._4wRecom.Q.push([‘setup’, function () {
$n._4wRecom.T.setTaxonomy(“/ansa/ansa/ansa.it/ambiente”);
$n._4wRecom.B.addPosition(“ansa_ansa_ambiente”,”NeoWidget”);
}]);
var x = d.createElement(e), s = d.getElementsByTagName(e)[0];
x.src = (‘https:’ == t.protocol ? ‘https://js-ssl’ : ‘http://js’)+o;
x.async = a;
s.parentNode.insertBefore(x, s);
}) (window,’scr’+’ipt’,’.neodatagroup.com/4wr.js’,document,1,location,1);
}
<![CDATA[]]>
<![CDATA[]]>